Pathology of Unclassifiable Myelodysplastic Syndromes
Before discussing the pathology of unclassifiable myelodysplastic syndromes (MDS-U), some background information is necessary.
The 2008 World Health Organization (WHO) classification of myelodysplastic syndromes (MDS) recognizes several clinicopathologic entities, defined by particular morphologic, cytogenetic, and clinical features. However, a small minority of MDS cases cannot be classified into any specific entity, because they bear features that are atypical, making their clinical significance uncertain. See the image below.
See Myelodysplastic Syndromes: Classification, Features, Diagnosis, and Treatment Options, a Critical Images slideshow, to help identify, classify, work up, and treat these disorders.
Rather than attempting to force such cases into a specific MDS diagnostic group (that may carry particular prognostic or therapeutic implications), placing such cases in a separate group known as “MDS, unclassifiable,” until sufficient data are available to better characterize their biologic features and clinical behavior is preferable. Thus, “myelodysplastic syndromes, unclassifiable” (MDS-U) encompasses cases of myelodysplasia (myeloid neoplasms characterized by ineffective hematopoiesis) that do not fulfill criteria for any of the specific MDS entities.
It is important to note that the MDS-U designation is not a wastebasket to be used for MDS cases in which the diagnostic workup is incomplete or some studies are suboptimal. Before the pathologist designates a case as MDS-U, any and all pertinent clinical, morphologic, immunophenotypic, or cytogenetic information that could enable classification as another MDS entity (or, indeed, another disease altogether) should be elicited.
Unlike the 2001 WHO classification, in which the unclassifiable myelodysplastic syndromes (MDS-U) group was a general designation of MDS cases that did not fit into any specific MDS entities,  the 2008 WHO classification recognizes 3 distinct scenarios that form the unclassifiable myelodysplastic syndromes (MDS-U) group, as follows  :
Cases of MDS with less than 5% bone marrow blasts that have 1% blasts in the peripheral blood
Cases of MDS with dysplasia limited to one lineage (refractory cytopenia with unilineage dysplasia [RCUD]) that have pancytopenia (hemoglobin < 10g/dL, absolute neutrophil count [ANC] < 1.8 x 109/L [see the Absolute Neutrophil Count calculator], and platelet counts < 100 x 109/L)
Cases presenting with persistent, unexplained cytopenia(s) that lack diagnostic morphologic features of MDS but bear a specific clonal bone marrow cytogenetic abnormality (see Immunophenotypic and Cytogenetic Features).
These 3 distinct scenarios are depicted in the following figure:
See also Pediatric Myelodysplastic Syndromes Pathology, Pathology of Acute Myeloid Leukemia With Myelodysplasia-Related Features, Pathology of Therapy-Related Myeloid Neoplasms, Pathology of Other Myeloid Related Precursor Neoplasms, Pathology of Acute Myeloid Leukemia Not Otherwise Categorized, and Pathology of Myeloid Proliferations Related to Down Syndrome
The incidence of unclassifiable myelodysplastic syndromes (MDS-U) is unknown; however, the incidence appears to represent only a small fraction of myelodysplastic syndrome (MDS) cases. In one series, unclassifiable myelodysplastic syndromes (MDS-U), as defined by the 2008 World Health Organization (WHO) classification criteria, comprised only 3% of MDS cases lacking excess bone marrow blasts. 
This represented a much smaller proportion of cases than when the 2001 WHO classification criteria were applied to the same cohort of cases, reflecting the more specific definition of unclassifiable myelodysplastic syndromes (MDS-U) in the 2008 versus the 2001 classification systems, as well as the broadening of the definition of certain other MDS entities. [3, 4] The relatively low proportion of unclassifiable myelodysplastic syndromes (MDS-U) cases in the new 2008 classification validates its use in assigning the vast majority of MDS cases to specific diagnostic groups with relatively defined biologic features and clinical behavior.
The clinical features of unclassifiable myelodysplastic syndromes (MDS-U) cases vary depending on the specific type. Common to all myelodysplastic syndrome (MDS) cases is that patients usually present with symptoms related to one or more cytopenias.
Although the clinical features of unclassifiable myelodysplastic syndromes (MDS-U) are varied, obtaining a detailed clinical history and complete blood cell (CBC) count with differentials is critical in order to exclude other, specific types of MDS that may masquerade as unclassifiable myelodysplastic syndromes (MDS-U). If the patient’s history includes chemotherapy or radiation therapy, the case should be classified as therapy-related MDS (t-MDS), not unclassifiable myelodysplastic syndromes (MDS-U). Therapy-related MDS may present with cytopenias and a cytogenetic abnormality in the absence of significant dysplasia, mimicking unclassifiable myelodysplastic syndromes (MDS-U) if the pertinent history is not elicited. 
The administration of exogenous growth factors such as granulocyte colony-stimulating factor (G-CSF) may transiently increase the peripheral blast count to a level of 1% (or higher). Thus, possible effects of growth factors should be excluded before diagnosing unclassifiable myelodysplastic syndromes (MDS-U) on the basis of 1% peripheral blasts; ideally, a peripheral smear should be examined at least 1 week off exogenous growth factors.
Finally, cases of refractory cytopenia with unilineage dysplasia (RCUD) may develop pancytopenia due to transient effects of drugs, toxins, infection, immune processes, or metabolic derangements. The pancytopenia should be shown to be persistent and unexplained (aside from ineffective hematopoiesis due to the MDS) before a case that would otherwise qualify as refractory cytopenias with underlying dysplasia is diagnosed as unclassifiable myelodysplastic syndromes (MDS-U).
Morphologic dysplasia in at least 1 lineage characterizes most types of unclassifiable myelodysplastic syndromes (MDS-U); cases with morphologic dysplasia are placed into the unclassifiable myelodysplastic syndromes (MDS-U) category if they have discordant cytopenias (pancytopenia with dysplasia limited to 1 lineage) or peripheral blood blast count (1% blasts in the peripheral blood with no increase in blasts in the bone marrow) (see the images below).
In the latter case, examining well-prepared peripheral smears and obtaining an accurate blast count on at least 200 cells in the peripheral smear is important; in smears with marked leukopenia, examination of a concentrated buffy coat may be helpful in ensuring sufficient cells to perform an accurate count.  The possibility that the marrow aspirate may be hemodilute and the case actually represents refractory anemia with excess blasts -1 or -2 (RAEB-1 or RAEB-2) with a nonrepresentative aspirate should be considered.
Cases with cytopenias that appear to lack significant morphologic dysplasia but bear an myelodysplastic syndrome (MDS)–defining cytogenetic abnormality should undergo careful examination of aspirate smears, peripheral blood, and bone marrow biopsy (the latter for megakaryocyte morphology, ideally examining at least 30 megakaryocytes) to ensure that morphologic dysplasia is not present in at least 10% of any lineage. Note that cases with a single cytopenia and dysplasia in a single but different lineage (such as anemia with dysplasia limited to the megakaryocytic lineage) are not classified as unclassifiable myelodysplastic syndromes (MDS-U); these cases are still considered within the spectrum of refractory cytopenia with unilineage dysplasia (RCUD).
In all cases of unclassifiable myelodysplastic syndromes (MDS-U) the possibility of a myeloproliferative neoplasm (MPN) or myelodysplastic/myeloproliferative overlap neoplasm (MDS/MPN) should be excluded. The presence of persistent peripheral blood monocytosis (> 1 x 109/L), thrombocytosis (≥ 450 x 109/L), or leukocytosis (≥ 13 x 109/L) in a case in which unclassifiable myelodysplastic syndromes (MDS-U) is considered should be placed in the MDS/MPN category. Cases that exhibit “proliferative-type” megakaryocyte morphology (enlarged, hyperlobated, and hyperchromatic megakaryocytes), splenomegaly, and bone marrow fibrosis may represent cases of primary myelofibrosis, mimicking MDS due to cytopenias and even morphologic dysplasia of neutrophils and erythroid elements that may occur in the later stages of disease.
No specific immunophenotype of unclassifiable myelodysplastic syndromes (MDS-U) exists. However, in cases with a hemodilute aspirate but with 1% peripheral blood blasts, CD34 staining of the bone marrow trephine biopsy may help disclose increased and/or clustered blasts.  If blasts appear to comprise at least 5% of the bone marrow biopsy cells by this method, a diagnosis of represent refractory anemia with excess blasts (RAEB) may be suggested rather than unclassifiable myelodysplastic syndromes (MDS-U).
Cytopenic patients lacking excess blasts or sufficient dysplasia in any lineage may be diagnosed with unclassifiable myelodysplastic syndromes (MDS-U) if any of certain cytogenetic abnormalities is detected on bone marrow karyotype. The following abnormalities are considered diagnostic of unclassifiable myelodysplastic syndromes (MDS-U) in such a situation  : -7, del(7q), -5, del(5q), i(17q), t(17p), -13, del(13q), del(11q), del(12p) or t(12p), del(9q), idic(X)(q13), t(11;16)(q23;p13.3), t(3;21)(q26;q22.1), t(1;3)(p36.3;q21.2), t(2;11)(p21;q23), inv(3)(q21q26.2), t(6;9)(p23;q34). However, many of these cytogenetic abnormalities can also be present in myeloproliferative neoplasm (MPN) and myelodysplastic/myeloproliferative overlap neoplasm (MDS/MPN) entities.
The following image is an example of a cytogenetic analysis.
When considering a diagnosis of unclassifiable myelodysplastic syndromes (MDS-U) based solely on a cytogenetic finding, other myeloid neoplasms must be carefully excluded by close examination of clinical data, such as the presence or absence of splenomegaly and a complete blood cell (CBC) count and differentials. JAK2 mutation analysis may also be helpful, as although JAK2 mutation is rare in myelodysplastic syndrome (MDS), it is relatively common in MPN and in some types of MDS/MPN. [8, 9] If the abnormality is present in all metaphases, a constitutional abnormality that may not be related to the cytopenia(s) should be considered.
Note that some abnormalities that are frequently observed in MDS cases, +8, -Y, and del(20q), are not considered diagnostic of MDS if these represent sole abnormalities; these cytogenetic abnormalities have been identified in patients with immune disorders and may not necessarily indicate a clonal stem cell abnormality. [10, 11] Aplastic anemia (AA) and immune thrombocytopenic purpura (ITP) are presumed to be immune-mediated processes that can exhibit cytogenetic abnormalities: trisomies of chromosome 6, 8, and 15; loss of the Y chromosome; as well as monosomy of chromosome 7 have been reported in aplastic anemia, and deletion of the long arm of chromosome 20 has been reported in ITP. [11, 12] Partly for these reasons, +8 and del(20q) abnormalities alone are considered insufficient to make a diagnosis of unclassifiablemyelodysplasticsyndromes (MDS-U).
However, the significance of a -7 abnormality (that is MDS-defining) in a hypoplastic marrow is less certain. Although some studies suggest that this abnormality confers a poor prognosis and lack of responsiveness to immunosuppression, supporting classification as unclassifiable myelodysplastic syndromes (MDS-U), some cases may still respond to immunosuppression, resembling aplastic anemia. [10, 13] Moreover, some cases of bona fide MDS respond to immunosuppression. 
Further study is needed to determine how best to classify and treat cases of hypoplastic marrow with cytogenetic abnormalities; these cases challenge our conceptualization of the distinction between MDS and aplastic anemia.
One particular scenario in which caution must be exercised is in patients with chronic myelogenous leukemia (CML) treated with tyrosine-kinase inhibitors (TKI). Such patients may develop cytogenetic abnormalities, including some that are considered MDS-defining, in remission from CML. Although these cases sometimes progress to MDS and acute myeloid leukemia (AML), in most instances they are transient. Thus, unclassifiable myelodysplastic syndromes (MDS-U) should not be diagnosed if a cytogenetic abnormality develops on TKI therapy in the absence of significant dysplasia or increased blasts. 
A study by Wang et al found that the WHO 2008 criteria for atypical chronic myeloid leukemia (aCML) identify a subgroup of patients with features clearly distinct from unclassifiable myelodysplastic/myeloproliferative neoplasm. 
Cases of unclassifiable myelodysplastic syndromes (MDS-U) should be followed carefully and should be reclassified as one of the defined myelodysplastic syndrome (MDS) subtypes if appropriate criteria are met after the initial evaluation (see Overview). Among cases lacking morphologic dysplasia but with a cytogenetic abnormality, the presence of monosomy 7 appears to be associated with evolution to other types of MDS (eg, refractory cytopenia with multilineage dysplasia [RCMD]) or acute leukemia. [13, 17]
Cases of unclassifiable myelodysplastic syndromes (MDS-U) that are placed into this category because of 1% peripheral blood blasts show a significantly poorer prognosis and higher incidence of transformation to acute myeloid leukemia (AML) than cases of refractory cytopenia with unilineage dysplasia (RCUD) or refractory cytopenia with multilineage dysplasia (RCMD), akin to refractory anemia with excess blasts-1 (RAEB-1).  Although it is recommended that only 1 or 2 cytopenias be allowed for patients with RCUD (thus requiring that cases with unilineage dysplasia but pancytopenia be classified as MDS-U), it is unclear if these patients have an inferior prognosis to RCUD patients. Further study is needed on this group of patients with unclassifiable myelodysplastic syndromes (MDS-U) to determine their clinical behavior.
Brunning RD, Bennett JM, Flandrin G, et al. Myelodysplastic syndrome, unclassifiable. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization Classification of Tumours Pathology and Genetics: Tumours of Haematopoietic and Lymphoid Tissues. 3rd ed. Lyon, France: IARC Press; 2001:72:
Orazi A, Brunning RD, Baumann I, Hasserjian RP. Myelodysplastic syndrome, unclassifiable. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press; 2008:103:
Hasserjian RP, Gupta P, Donohue K, et al. Application of the 2008 WHO Classification criteria for myelodysplastic syndromes without excess blasts: observations from Cancer and Leukemia Group B Study 10105 [abstract]. Mod Pathol. 2009;22 (suppl 1):266A.:
Verburgh E, Achten R, Louw VJ, Brusselmans C, Delforge M, Boogaerts M, et al. A new disease categorization of low-grade myelodysplastic syndromes based on the expression of cytopenia and dysplasia in one versus more than one lineage improves on the WHO classification. Leukemia. 2007 Apr. 21(4):668-77. [Medline].
Steensma DP, Dewald GW, Hodnefield JM, Tefferi A, Hanson CA. Clonal cytogenetic abnormalities in bone marrow specimens without clear morphologic evidence of dysplasia: a form fruste of myelodysplasia?. Leuk Res. 2003 Mar. 27(3):235-42. [Medline].
Brunning RD, Orazi A, Germing U, et al. Myelodysplastic syndromes/neoplasms, overview. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. . 4th ed. Lyon, France: IARC Press; 2008:89, 93.:
Soligo D, Delia D, Oriani A, Cattoretti G, Orazi A, Bertolli V, et al. Identification of CD34+ cells in normal and pathological bone marrow biopsies by QBEND10 monoclonal antibody. Leukemia. 1991 Dec. 5(12):1026-30. [Medline].
Steensma DP, Dewald GW, Lasho TL, Powell HL, McClure RF, Levine RL, et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both “atypical” myeloproliferative disorders and myelodysplastic syndromes. Blood. 2005 Aug 15. 106(4):1207-9. [Medline]. [Full Text].
Wang SA, Hasserjian RP, Loew JM, Sechman EV, Jones D, Hao S, et al. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis harbors JAK2 mutation and shows overlapping myeloproliferative and myelodysplastic features. Leukemia. 2006 Sep. 20(9):1641-4. [Medline].
Gupta V, Brooker C, Tooze JA, Yi QL, Sage D, Turner D, et al. Clinical relevance of cytogenetic abnormalities at diagnosis of acquired aplastic anaemia in adults. Br J Haematol. 2006 Jul. 134(1):95-9. [Medline].
Soupir CP, Vergilio JA, Kelly E, Dal Cin P, Kuter D, Hasserjian RP. Identification of del(20q) in a subset of patients diagnosed with idiopathic thrombocytopenic purpura. Br J Haematol. 2009 Mar. 144(5):800-2. [Medline].
Keung YK, Pettenati MJ, Cruz JM, Powell BL, Woodruff RD, Buss DH. Bone marrow cytogenetic abnormalities of aplastic anemia. Am J Hematol. 2001 Mar. 66(3):167-71. [Medline].
Maciejewski JP, Risitano A, Sloand EM, Nunez O, Young NS. Distinct clinical outcomes for cytogenetic abnormalities evolving from aplastic anemia. Blood. 2002 May 1. 99(9):3129-35. [Medline].
Sloand EM, Wu CO, Greenberg P, Young N, Barrett J. Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. J Clin Oncol. 2008 May 20. 26(15):2505-11. [Medline].
Jabbour E, Kantarjian HM, Abruzzo LV, O’Brien S, Garcia-Manero G, Verstovsek S, et al. Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood. 2007 Oct 15. 110(8):2991-5. [Medline].
Wang SA, Hasserjian RP, Fox PS, et al. Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. Blood. 2014 Apr 24. 123 (17):2645-51. [Medline].
Wimazal F, Fonatsch C, Thalhammer R, Schwarzinger I, Mullauer L, Sperr WR, et al. Idiopathic cytopenia of undetermined significance (ICUS) versus low risk MDS: the diagnostic interface. Leuk Res. 2007 Nov. 31(11):1461-8. [Medline].
Knipp S, Strupp C, Gattermann N, Hildebrandt B, Schapira M, Giagounidis A, et al. Presence of peripheral blasts in refractory anemia and refractory cytopenia with multilineage dysplasia predicts an unfavourable outcome. Leuk Res. 2008 Jan. 32(1):33-7. [Medline].
Robert P Hasserjian, MD Associate Professor of Pathology, Harvard Medical School; Associate Pathologist, Massachusetts General Hospital
Disclosure: Nothing to disclose.
Cherie H Dunphy, MD, FCAP, FASCP Professor of Pathology and Laboratory Medicine, Diector of Hematopathology and Hematopathology Fellowship, Associate Director, Core, Flow Cytometry, and Special Procedures Laboratories, Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill School of Medicine
Cherie H Dunphy, MD, FCAP, FASCP is a member of the following medical societies: American Society for Clinical Pathology, College of American Pathologists, International Academy of Pathology, North Carolina Medical Society, Children’s Oncology Group
Disclosure: Nothing to disclose.
Pathology of Unclassifiable Myelodysplastic Syndromes
Research & References of Pathology of Unclassifiable Myelodysplastic Syndromes|A&C Accounting And Tax Services